Hypothesis

Wang, Wenguang; Liu, Chao; Cong, Hongliang

doi:10.1177/1074248416651721

Cited by 3 publications

(1 citation statement)

References 88 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EPISODE trial, in its 3rd phase, assesses the effect of PCSK9 inhibitors on CAVD (Clinicaltrials.gov ID: NCT04968509) based on the established reduction in atherogenic lipoprotein cholesterol-carrying particles such as Lp(a) 92 with the use of PCSK9 inhibitors. The results of this ongoing trial might necessitate potential therapeutic alterations to the current guidelines for AS management.…”

Section: Emerging Therapeutic Modalities For Calcific Asmentioning

confidence: 99%

Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies

Jain,

Goyal,

Khan

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Aortic valve stenosis is a disease characterized by thickening and narrowing of the aortic valve (AV), most commonly due to calcification, which leads to left ventricular outflow obstruction called calcific aortic valve disease (CAVD). CAVD presents as a progressive clinical syndrome with cardiorespiratory symptoms, often with rapid deterioration. The modern-day pathophysiology of CAVD involves a complex interplay of genetic factors, chronic inflammation, lipid deposition, and valve calcification, with early CAVD stages resembling atherosclerosis. Various imaging modalities have been used to evaluate CAVD, with a recent trend of using advanced imaging to measure numerous AV parameters, such as peak jet velocity. Significant improvements in mortality have been achieved with transcatheter AV repair, but numerous therapeutics and modalities are being researched to delay the progression of CAVD. This article aims to provide a comprehensive review of CAVD, explore recent developments, and provide insights into future treatments with various novel modalities.

show abstract

Section: Emerging Therapeutic Modalities For Calcific Asmentioning

confidence: 99%

Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies

Jain,

Goyal,

Khan

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

Editorial commentary: Lp(a) and calcific aortic valve stenosis: Direct LPA targeting or PCSK9-Lowering therapy?

Capoulade

Cariou

2021

Trends in Cardiovascular Medicine

View full text Add to dashboard Cite

PCSK9 in cholesterol metabolism: from bench to bedside

et al. 2018

View full text Add to dashboard Cite

Dyslipidemia, and specifically elevated low-density lipoprotein (LDL) cholesterol, is one of the most important cardiovascular risk factors. Statins are considered first line therapy for the primary and secondary prevention of cardiovascular disease. However, statins may not be adequate treatment for elevated circulating LDL levels and are ineffective in certain familial hypercholesterolemias. The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulatory protein that affects LDL receptors, offers a new alternative for these patients. Moreover, gain-of-function mutations were discovered to be the root cause of familial autosomal dominant hypercholesterolemia. Inhibition of PSCK9 reduces plasma LDL levels, even in patients for whom statins are ineffective or not tolerated. Alirocumab and evolocumab, human monoclonal antibodies that inhibit PCSK9, have been approved to lower LDL levels. While there are drawbacks to these treatments, including adverse events, administration by subcutaneous injection, and high cost, these drugs are indicated for the treatment of atherosclerotic cardiovascular disease and familial hypercholesterolemia as adjunct to diet and maximally tolerated statin therapy. PCSK9 inhibitors may work synergistically with statins to lower LDL. Novel approaches to PCSK9 inhibition are currently in development with the aim of providing safe and effective treatment options to decrease cardiovascular event burden, ideally at lower cost and with oral bioavailability.

show abstract

Hypothesis

Cited by 3 publications

References 88 publications

Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies

Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies

Editorial commentary: Lp(a) and calcific aortic valve stenosis: Direct LPA targeting or PCSK9-Lowering therapy?

PCSK9 in cholesterol metabolism: from bench to bedside

Contact Info

Product

Resources

About